Alpha Tau MedicalDRTS +4.67%28 Return-on-Tangible-Equity is -125.31% as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,196 Biotechnology companies, Alpha Tau Medical ranks worse than 66.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Alpha Tau Medical's annualized net income for the quarter that ended in Mar. 2026 was $-91.76 Mil. Alpha Tau Medical's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $73.23 Mil. Therefore, Alpha Tau Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -125.31%.
The historical rank and industry rank for Alpha Tau Medical's Return-on-Tangible-Equity or its related term are showing as below:
DRTS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -95.27 Med: -52.08 Max: -30.67
Current: -77.49
During the past 7 years, Alpha Tau Medical's highest Return-on-Tangible-Equity was -30.67%. The lowest was -95.27%. And the median was -52.08%.
DRTS's Return-on-Tangible-Equity is ranked worse than 66.05% of 1196
companies
in the Biotechnology industry
Industry Median: -42.19
vs DRTS: -77.49
Alpha Tau Medical (NAS:DRTS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Alpha Tau Medical Return-on-Tangible-Equity Related Terms
Alpha Tau Medical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRTS vs ORIC, OLMA, KURA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Alpha Tau Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -125.31% mean?
Alpha Tau Medical (DRTS) has a Return-on-Tangible-Equity of -125.31% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #790 out of 1196 companies in the Biotechnology industry, placing it in the top 66.1%.
Is Alpha Tau Medical's Return-on-Tangible-Equity too high?
Alpha Tau Medical's current Return-on-Tangible-Equity is -125.31%. Based on the distribution chart, Alpha Tau Medical ranks #790 out of 1196 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Return-on-Tangible-Equity compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #790 out of 1196 companies for Return-on-Tangible-Equity. This places Alpha Tau Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current Return-on-Tangible-Equity is -125.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Return-on-Tangible-Equity of -125.31%. The current Return-on-Tangible-Equity is -125.31%. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Return-on-Tangible-Equity is -125.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
